A Phase 2 interventional study of Glycopyrrolate (85 μg) and Glycopyrrolate (42.5 μg) in Chronic Obstructive Pulmonary Disease, sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA. Completed at 7 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 53rd largest by enrollment, is one of 3 that started in 2024, is one of 19 in phase 2, and was the 68th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, one of the names counted as Merck & Co., Inc. Under that name alone:
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 15 (65%) have results posted.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, this one is the 16th largest by enrollment, is one of 2 that started in 2024, is one of 18 in phase 2, and was the 23rd registered.
Merck & Co., Inc’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2002.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 26 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, double-blind, placebo-controlled complete block cross-over study designed to assess the efficacy, safety, and pharmacokinetics of 3 dose levels of glycopyrrolate inhalation solution delivered twice daily via standard jet nebulizer over three 1-week active treatment periods and one 1-week placebo period in subjects with chronic obstructive pulmonary disease (COPD).
Participants enrolled will be expected to participate for approximately 10 weeks;1-2 weeks for screening, four 1-week treatment periods separated by 1 week of washout between each treatment, and 1 week of follow-up. Participants will be randomized to a treatment sequence, 1-4, which will determine the order that they receive the dose levels during the four treatment periods of the study. Neither participants nor study staff will know which dose a participant is receiving in any given treatment period. All participants will receive all 4 dose levels and it is expected that each participant completes all four treatment periods in their assigned sequence. The primary objective of this study is to evaluate the bronchodilator effect of twice daily inhaled glycopyrrolate solution over a dose range administered by standard jet nebulizer in subjects with COPD on Day 7, to support the selection of the glycopyrrolate doses for further clinical development in a fixed-dose combination with ensifentrine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females are eligible to participate if they are not pregnant, not breastfeeding, and ≥ 1 of the following conditions apply:
Post-bronchodilator (4 puffs of salbutamol) spirometry at Screening demonstrating both the following:
Exclusion Criteria:
Within 6 months prior to Screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to
Drug: Glycopyrrolate (85 μg)
The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to
Drug: Glycopyrrolate (42.5 μg)
The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to
Drug: Glycopyrrolate (14 μg)
The treatment period will be 7 days, followed by a 7-day washout period, before beginning the next treatment in the sequence they were assigned to
Drug: Placebo
Administered by a standard jet nebulizer, twice daily for 7 consecutive days
Administered by a standard jet nebulizer, twice daily for 7 consecutive days
Administered by a standard jet nebulizer, twice daily for 7 consecutive days
Administered by a standard jet nebulizer, twice daily for 7 consecutive days
Change From Average Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1)
Time frame: Baseline (pre-dose for each treatment period) and Day 7
Change From Average Baseline FEV1 to Average Peak FEV1 Measured Over 4 Hours
Time frame: Baseline (pre-dose for each treatment period) and Day 7
Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 4 Hours (AUC0-4h)
The endpoint is measured as AUC/4 hour time interval resulting in an average volume measure in liters.
Time frame: Baseline (pre-dose for each treatment period) and Day 7
Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 12 Hours (AUC0-12h)
The endpoint is measured as AUC/12 hour time interval resulting in an average volume measure in liters.
Time frame: Baseline (pre-dose for each treatment period) and Day 7
Change From Average Baseline FEV1 to Evening Trough FEV1
Time frame: Baseline (pre-dose for each treatment period) and Day 7
Change From Average Baseline FEV1 to Peak FEV1 Measured Over 4 Hours After First Dose
Time frame: Baseline (pre-dose) and Day 1
Change From Average Baseline FEV1 to Average FEV1 AUC0-4h Measured After First Dose
The endpoint is measured as AUC/4 hour time interval resulting in an average volume measure in liters.
Time frame: Baseline (pre-dose) and Day 1
Number of Treatment Emergent Adverse Events (TEAEs)
Time frame: From first dose through the follow-up contact (approximately 8 weeks per participant). Overall safety data was collected for 5 months total.
Glycopyrronium Free Base AUC0-12h
Time frame: After morning dose Day 7
Glycopyrronium Free Base Maximum Plasma Drug Concentration (Cmax)
Time frame: After morning dose Day 7
Glycopyrronium Free Base Time to Maximum Plasma Drug Concentration (Tmax)
Time frame: After morning dose Day 7
Demographic and baseline characteristics are presented by sequence assignment based on which treatment sequence the participant was randomized to. Each treatment sequence was comprised of four treatment periods with a different dose level being received during each period. Therefore, each participant received each dose and there is no demographic or baseline data based dose alone.
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 |
|---|---|---|---|---|
| Started | 12 | 11 | 12 | 11 |
| Completed | 10 | 11 | 11 | 9 |
| Not completed | 2 | 0 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Not wanting further contact | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal of consent | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal due to hurricane | 0 | 0 | 1 | 0 |
| Liters | Dose Level A Glycopyrrolate (85 μg) | Dose Level B Glycopyrrolate (42.5 μg) | Dose Level C Glycopyrrolate (14 μg) | Dose Level D (Placebo) |
|---|---|---|---|---|
| Change From Average Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) | 0.0525 ± 0.02125 | 0.0393 ± 0.02135 | 0.0115 ± 0.02069 | -0.0287 ± 0.02029 |
| Liters | Dose Level A Glycopyrrolate (85 μg) | Dose Level B Glycopyrrolate (42.5 μg) | Dose Level C Glycopyrrolate (14 μg) | Dose Level D (Placebo) |
|---|---|---|---|---|
| Change From Average Baseline FEV1 to Average Peak FEV1 Measured Over 4 Hours | 0.2333 ± 0.02304 | 0.2042 ± 0.02314 | 0.1568 ± 0.02243 | 0.0520 ± 0.02200 |
The endpoint is measured as AUC/4 hour time interval resulting in an average volume measure in liters.
| Liters | Dose Level A Glycopyrrolate (85 μg) | Dose Level B Glycopyrrolate (42.5 μg) | Dose Level C Glycopyrrolate (14 μg) | Dose Level D (Placebo) |
|---|---|---|---|---|
| Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 4 Hours (AUC0-4h) | 0.0969 ± 0.02037 | 0.0693 ± 0.02046 | 0.0418 ± 0.01984 | -0.0403 ± 0.01945 |
The endpoint is measured as AUC/12 hour time interval resulting in an average volume measure in liters.
| Liters | Dose Level A Glycopyrrolate (85 μg) | Dose Level B Glycopyrrolate (42.5 μg) | Dose Level C Glycopyrrolate (14 μg) | Dose Level D (Placebo) |
|---|---|---|---|---|
| Change From Average Baseline FEV1 to Average FEV1 Area Under the Curve Versus Time From Time 0 to 12 Hours (AUC0-12h) | 0.0916 ± 0.02006 | 0.0656 ± 0.02031 | 0.0338 ± 0.02039 | -0.0449 ± 0.01927 |
| Liters | Dose Level A Glycopyrrolate (85 μg) | Dose Level B Glycopyrrolate (42.5 μg) | Dose Level C Glycopyrrolate (14 μg) | Dose Level D (Placebo) |
|---|---|---|---|---|
| Change From Average Baseline FEV1 to Evening Trough FEV1 | 0.0652 ± 0.02054 | 0.0569 ± 0.02066 | 0.0091 ± 0.02115 | -0.0484 ± 0.01996 |
| Liters | Dose Level A Glycopyrrolate (85 μg) | Dose Level B Glycopyrrolate (42.5 μg) | Dose Level C Glycopyrrolate (14 μg) | Dose Level D (Placebo) |
|---|---|---|---|---|
| Change From Average Baseline FEV1 to Peak FEV1 Measured Over 4 Hours After First Dose | 0.2117 ± 0.01786 | 0.1872 ± 0.01798 | 0.1643 ± 0.01675 | 0.0730 ± 0.01716 |
The endpoint is measured as AUC/4 hour time interval resulting in an average volume measure in liters.
| Liters | Dose Level A Glycopyrrolate (85 μg) | Dose Level B Glycopyrrolate (42.5 μg) | Dose Level C Glycopyrrolate (14 μg) | Dose Level D (Placebo) |
|---|---|---|---|---|
| Change From Average Baseline FEV1 to Average FEV1 AUC0-4h Measured After First Dose | 0.1377 ± 0.01498 | 0.1027 ± 0.01507 | 0.0859 ± 0.01405 | 0.0000 ± 0.01439 |
| Events | Dose Level A Glycopyrrolate (85 μg) | Dose Level B Glycopyrrolate (42.5 μg) | Dose Level C Glycopyrrolate (14 μg) | Dose Level D (Placebo) |
|---|---|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAEs) | 13 | 8 | 7 | 15 |
| h*pg/mL | Dose Level A Glycopyrrolate (85 μg) | Dose Level B Glycopyrrolate (42.5 μg) | Dose Level C Glycopyrrolate (14 μg) |
|---|---|---|---|
| Glycopyrronium Free Base AUC0-12h | 256 ± 187.7 | 108 ± 66.22 | 38.4 ± 18.25 |
| pg/mL | Dose Level A Glycopyrrolate (85 μg) | Dose Level B Glycopyrrolate (42.5 μg) | Dose Level C Glycopyrrolate (14 μg) |
|---|---|---|---|
| Glycopyrronium Free Base Maximum Plasma Drug Concentration (Cmax) | 53.7 ± 38.46 | 24.7 ± 13.87 | 9.27 ± 5.354 |
| hours | Dose Level A Glycopyrrolate (85 μg) | Dose Level B Glycopyrrolate (42.5 μg) | Dose Level C Glycopyrrolate (14 μg) |
|---|---|---|---|
| Glycopyrronium Free Base Time to Maximum Plasma Drug Concentration (Tmax) | 0.33 (0 to 1.63) | 0.33 (0 to 0.77) | 0.43 (0.25 to 1.25) |
Collected over Adverse event data was collected over a 5-month period, however individual participant data was collected only for 8 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level A Glycopyrrolate (85 μg) | 0/40 (0%) | 2/40 (5%) | 0/40 (0%) |
| Dose Level B Glycopyrrolate (42.5 μg) | 0/40 (0%) | 1/40 (2.5%) | 0/40 (0%) |
| Dose Level C Glycopyrrolate (14 μg) | 0/41 (0%) | 0/41 (0%) | 0/41 (0%) |
| Dose Level D (Placebo) | 0/43 (0%) | 1/43 (2.3%) | 0/43 (0%) |
| Event | Dose Level A Glycopyrrolate (85 μg) | Dose Level B Glycopyrrolate (42.5 μg) | Dose Level C Glycopyrrolate (14 μg) | Dose Level D (Placebo) |
|---|---|---|---|---|
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 2/40 | 0/40 | 0/41 | 1/43 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 1/40 | 0/40 | 0/41 | 0/43 |
| INJURYInjury, poisoning and procedural complications | 0/40 | 1/40 | 0/41 | 0/43 |
| Age, Continuous(Years) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| Mean | 63.5 ± 7.15 | 68.7 ± 4.54 | 62.5 ± 9.17 | 66.1 ± 6.28 | 65.1 ± 7.24 |
| Sex: Female, Male(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| Female | 8 | 6 | 7 | 7 | 28 |
| Male | 4 | 5 | 5 | 4 | 18 |
| Race/Ethnicity, Customized(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| White | 9 | 9 | 12 | 10 | 40 |
| Black | 3 | 2 | 0 | 1 | 6 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 0 |
| Multiple | 0 | 0 | 0 | 0 | 0 |
| Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| HISPANIC OR LATINO | 1 | 0 | 0 | 0 | 1 |
| NOT HISPANIC OR LATINO | 10 | 11 | 12 | 9 | 42 |
| NOT REPORTED | 1 | 0 | 0 | 2 | 3 |
| Region of Enrollment(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| United States | 12 | 11 | 12 | 11 | 46 |
| Body mass index(kg/m^2) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| Mean | 29.68 ± 6.284 | 29.04 ± 2.363 | 28.98 ± 9.098 | 27.55 ± 4.473 | 28.83 ± 6.016 |
| Childbearing potential(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Total |
|---|---|---|---|---|---|
| Yes | 0 | 0 | 0 | 0 | 0 |
| No | 8 | 6 | 7 | 7 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2024 to primary completion in Jan 2025, 4 months.
Results were first posted in Feb 2026, 1 year 1 month after primary completion.
Of 120 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 4 months is below that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA →